Av
I maj publicerades resultat ur WHOs internationella studie Interphone och forskarna meddelade att mobiltelefoner inte ökade risken för att utveckla hjärntumörer för låganvändare. Däremot såg forskarna en eventuell ökad risk förutveckling av hjärntumörer hos de extrema exponeringsgrupperna, som använde mobiltelefon en halvtimme dagligen vilket räknas som dagens normalanvändare, men förordade en försiktig tolkning av resultaten och krävde mer forskning. Örebro Universitetssjukhus publicerar nu en studie som bekräftar farhågorna i Interphone-studien.
Resultaten från Interphone innefattade inte data från personer i åldersspannen 20-29 år samt 60-80 år. Inte heller räknades användare av trådlösa bordstelefoner in. Försökspersonerna avgränsades till personer som fått hjärntumörer när de var mellan 30-59 år. I Örebrostudien var urvalet bredare och innefattade hjärntumörpatienter i åldrarna 20-80 år.
När beräkningar gjordes på resultaten som redovisades i maj för Interphone-studien var taket för den högst exponerade gruppen 1640 timmar eller mer. Utslaget på tio år, som studiens data innefattade, motsvarade det en mobilanvändning på en halvtimme om dagen. Men Örebroforskarna höjde taket ytterligare, till 2000 timmar eller mer, för att analysera risken för de extremt exponerade användarna.
När resultaten från Interphone-studien beräknas på nytt utifrån samma kriterier som Örebro-studien, visar det sig att de extrema mobilanvändarna löper fördubblad risk för att utveckla elakartad hjärntumör på samma sida av hjärnan som mobilen används.
Resultaten publiceras i det senaste numret av International Journal of Epidemiology.
Resultaten från Interphone innefattade inte data från personer i åldersspannen 20-29 år samt 60-80 år. Inte heller räknades användare av trådlösa bordstelefoner in. Försökspersonerna avgränsades till personer som fått hjärntumörer när de var mellan 30-59 år. I Örebrostudien var urvalet bredare och innefattade hjärntumörpatienter i åldrarna 20-80 år.
När beräkningar gjordes på resultaten som redovisades i maj för Interphone-studien var taket för den högst exponerade gruppen 1640 timmar eller mer. Utslaget på tio år, som studiens data innefattade, motsvarade det en mobilanvändning på en halvtimme om dagen. Men Örebroforskarna höjde taket ytterligare, till 2000 timmar eller mer, för att analysera risken för de extremt exponerade användarna.
När resultaten från Interphone-studien beräknas på nytt utifrån samma kriterier som Örebro-studien, visar det sig att de extrema mobilanvändarna löper fördubblad risk för att utveckla elakartad hjärntumör på samma sida av hjärnan som mobilen används.
Resultaten publiceras i det senaste numret av International Journal of Epidemiology.
"We offer effective staffing solutions provided by specialists, we understand a company’s specific needs and we know where to find the best talent." 
"Mercodia has been a supplier of reliable assays since 1991" 
"To develop innovative and effective pharmaceuticals within autoimmune/ inflammatory diseases and cancer where major medical need exists" 
"Novel products for CVD treatment and prevention." 
"To supply Swedish and Danish laboratories with laboratory equipment and furniture of highest quality and offer service on all delivered products." 
"Medivir is a specialty pharmaceutical company with unique positioning on the Nordic market and our goal is become a profitable company in high growth" 
"We are recognized as a flexible partner with short decision and lead times plus a proven record for the highest quality and cost efficiency." 
"To become an internationally leading dental company with innovative, proprietary products of high therapeutic and commercial value." 
"To be the most attractive node and business platform in the Nordic countries for new and innovative Life Science companies" 
"Our services in ligand-based and structure-based drug design is a cost-efficient alternative for smaller pharmaceutical companies" 
"Our goal is to invest in innovations and develop new unique pharmaceuticals" 
"We aim to be the pioneering benchmark in user-friendly software experience in combination with the highest level of quality." 
"TFS is today the leading European development partner for biopharmaceutical companies in their global clinical development process." 
"PCG - a professional full service CRO for your clinical trials.
Powered by Viedoc, globally trusted eCRF, keeping trials within budget and timelines" 
"Your global partner of pharmaceutical service and cGMP manufacturing" 
"APL provides high-quality services to Life Science. We are a Dedicated Partner from Discovery to Market." 
"Our products enable an increased number of transplants leading to substantial cost savings for society and increased quality of life for patients." 
"The PolyPeptide Group is a world class manufacturer of peptide active pharmaceutical ingredients." 
"We turn medical research into applications for better health and well-being." 
"Our organisation value is to contribute to positioning Scandinavian healthcare and research in absolute world class." 
"Dilafor is developing new products in the field of obstetrics, to provide an effective solution to the challenge of dystocia or protracted labor"
" 
"Our vision is to become one of the top 10 global providers of scientific instruments; we will get there by striving for market leadership in our respective product and application niches."
" 
"We are entirely devoted to luminescence technology." 
"Anton Paar is a product and service leader in the field of scientific instruments. We deliver uncompromised quality in everything we do." 
"Our reliability, customer service, global network and integrated technology make World Courier service truly "A service no one else can deliver"." 
"Best in class companies see the value of optimising their business by having an effective strategy for information management and documentation." 
"We are making it more attractive for companies to invest in innovation with reduced corporation tax on profits from patents to 10%." 
"We promise to go the extra mile every day to ensure you receive the highest level of service and value with each shipment you entrust to us." 
"To be acknowledged as the Best-in-Class provider of pharmaceutical development and manufacturing services by customers, employees & other stakeholders" 
"Discover your possibilities in one of Europe´s most productive life science regions. Welcome to Stockholm-Uppsala."
" 
"As a full service CRO with offices in all Nordic countries we can provide our customer with professional support throughout the clinical research." 
"Allenex is a life science company that develops, manufactures, markets and sells high quality products for the transplantation market." 
"Your work is important to us, we are committed to your success.
Innovative tools? Please download the Promega app." 
"Our aim is to be the best drug development partner to the biotechnology and pharmaceutical industry no matter where you are based." 
"Together with Zacco our clients achieve their business goals through the management of their intellectual property." 
"We have a unique technological platform, built around 5HT-receptor antagonism, for the treatment of inflammation and pain"." 
"We help our clients create significant business value through scientific expertise." 
"Innovation takes place when biology meets engineering; ICT is an enabler to solve the needs for increased functionality and reduced cost in Life Science" 
"To adapt Competent Authorities´ requirements into opportunities is not just an artform - today it´s a business necessity." 
"Uppsala BIO is a life science pathfinder. We build ways to make life science flourish, in cooperation with industry, academia, society and healthcare." 
"VWR is a global laboratory distributor of chemicals, life science products, consumables, equipment, instruments, furniture, e-commerce and services" 
"With our first class products and our committed and skilled colleagues we guarantee our customers the best support in the market, at no extra charge." 
